Emil Hristov is an associate in Ropes & Gray’s antitrust team in London. Prior to joining the firm, Emil was an associate at another international law firm in its Frankfurt and Brussels offices.
Emil advises clients on all aspects of EU and German competition/antitrust laws and has significant experience in foreign investment review procedures across jurisdictions, facilitating the establishment of a dedicated FDI practice at his previous firm. He guides clients through antitrust compliance questions concerning business practices and cooperation agreements. Emil has a strong focus on assisting companies in the life sciences space and has advised technology and media clients in obtaining merger control and FDI clearances in the context of global transactions. His experience includes representing clients before the EU Commission, the German Federal Cartel Office, the German Ministry of Economic Affairs and Climate Action and coordinating multijurisdictional fillings.
Emil is a German-qualified lawyer, admitted to the Frankfurt am Main Bar and has graduated from the University of Heidelberg.
Experience
- Advised Pfizer and securing regulatory clearances in the context of several transactions, including: the spin-off and sale of its Upjohn division to Mylan NV; its divestment of Meridian Medical Technologies; its $6.7 billion acquisition of Arena Pharmaceuticals; its $43 billion acquisition of Seagen Inc.*
- Advised Boston Scientific and securing regulatory clearances in the context of several transactions, including: its $1.07 billion acquisition of Lumenis; its acquisition of Baylis Medical Company Inc.; its $295 million acquisition of the remaining interest of Farapulse Inc.; its $ 615 million acquisition of Apollo Endosurgery; its $1.16 billion acquisition of Silk Road Medical; its $3.7 billion acquisition of Axonics, Inc.*
- Advised Novo Nordisk A/S and securing FDI clearances in connection with its $11 billion acquisition of three fill-finish sites from Novo Holdings A/S, which Novo Holdings had acquired from Catalent, Inc.*
- Advised Bristol-Myers Squibb and securing regulatory clearances in the context of several transactions, including: its $4.1 billion acquisition of Turning Point Therapeutics; its $ 5.8 billion acquisition of Mirati Therapeutics*
- Advised Palo Alto Networks and securing regulatory clearances for the acquisition of IBM’s QRadar Software as a Service assets*
- Advised AT&T and securing FDI clearances for its $43 billion sale of WarnerMedia to Discovery*
- Advised a client in the life sciences space on a complaint before the EU Commission against potential excessive pricing practices*
Credentials
Presentations
Memberships & Affiliations
Disclaimer
Ropes & Gray International LLP is a limited liability partnership registered in Delaware, United States of America and is a recognised body regulated by the Solicitors Regulation Authority (with registered number 521000).